BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 15, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Oct. 23, 2023

Oct. 23, 2023
Med-tech firms raising money in public or private financings, including: Aurora.
Read More

Financings for Oct. 23, 2023

Oct. 23, 2023
Biopharmas raising money in public or private financings, including: Aligos, Applied Molecular Transport, Cyclo, Harpoon.
Read More

Abivax gains US listing, pads coffers with $236M in Nasdaq IPO

Oct. 20, 2023
By Jennifer Boggs
Abivax SA’s debut on the U.S. market received a somewhat chilly reception Oct. 20, as the firm priced on the low end of its proposed range and ended the first day of trading in the red. But the company managed to pull in about $235.8 million in gross proceeds, the majority of which will support late-stage efforts for obefazimod, an oral candidate with a novel mechanism of action it hopes to advance in the lucrative inflammatory bowel disease space.
Read More

Financings for Oct. 20, 2023

Oct. 20, 2023
Biopharmas raising money in public or private financings, including: Arcutis, Adial, Talaris, Tourmaline.
Read More

Financings for Oct. 19, 2023

Oct. 19, 2023
Biopharmas raising money in public or private financings, including: Abivax, Ultragenyx.
Read More

Financings for Oct. 19, 2023

Oct. 19, 2023
Med-tech firms raising money in public or private financings, including: Evident Vascular, Oxford Nanopore, Vitatek.
Read More

Financings for Oct. 18, 2023

Oct. 18, 2023
Biopharmas raising money in public or private financings, including: Actym, Ambrx, Celcuity, Ultragenyx.
Read More

Financings for Oct. 18, 2023

Oct. 18, 2023
Med-tech firms raising money in public or private financings, including: Infobionic, Variantyx.
Read More

Financings for Oct. 17, 2023

Oct. 17, 2023
Biopharmas in Asia-Pacific raising money in public or private financings: Jiangsu Atom Bioscience.
Read More
Dollar sign thermometer

Despite challenges, Q3 strongest quarter for biopharma financings in 2023

Oct. 17, 2023
By Karen Carey
Biopharma financings in 2023 – at $49.3 billion raised through the third quarter (Q3) – are tracking ahead of, or only slightly behind, several years since 2011, except for the two outlier years of 2020 and 2021 when there was a flurry of investments in response to the COVID-19 pandemic.
Read More
Previous 1 2 … 235 236 237 238 239 240 241 242 243 … 665 666 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing